Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies

Correction to: Mol Cancer

https://doi.org/10.1186/s12943-018-0779-z

Following publication of the original article [1], the authors reported an error in Table 1. Incorrect value was placed under Efficacy (column), R/R non-GCB DLBCL (row).The value 92% was captured instead of 35%. Corrected table is shown below. The authors would like to apologize for this error.

Table 1.

Clinical trials with BTK inhibitors in B cell malignancies

Patient population	Therapeutic regimen	Phase	Efficacy	Ref
R/R CLL	Ibrutinib	Ib/II	ORR (71%), PR (20%)	[11]
R/R CLL	Ibrutinib	III	ORR (63%)	[248]
TN CLL	Ibrutinib	Ib/II	ORR (85%), CR (26%)	[199]
TN CLL	Ibrutinib	III	ORR (86%), CR (4%)	[13]
R/R MCL	Ibrutinib	II	ORR (68%), CR (21%)	[187]
R/R MCL	Ibrutinib	III	ORR (72%), CR (19%)	[249]
R/R WM	Ibrutinib	II	ORR (91%), Major response (73%)	[188]
R/R ABC-DLBCL	Ibrutinib	II	ORR (37%)	[196]
R/R CLL	Ibrutinib-Rituximab	II	ORR (95%), CR (8%)	[250]
R/R CLL	Ibrutinib-bendamustine-rituximab	III	ORR (83%), CR (10%)	[251]
R/R MCL	Ibrutinib-Rituximab	II	ORR (88%), CR (44%), PR (44%)	[252]
R/R CLL	Acalabrutinib	I/II	ORR (95%)	[12]
R/R	Acalabrutinib	II	ORR (81%), CR (40%), PR (41%)	[219]
R/R CLL	ONO/GS-4059	I	ORR (96%)	[222]
R/R MCL	ONO/GS-4059	I	ORR (92%)	[222]
R/R non-GCB DLBCL	ONO/GS-4059	I	ORR (35%)	[222]
R/R CLL	BGB-3111	I	ORR (90%)	[221, 253]
R/R MCL	BGB-3111	I	ORR (80%)	[253]
R/R MZL	Ibrutinib	II	ORR (51%)	[254]
R/R FL	Ibrutinib	I	ORR (38%)	[186]

CLL Chronic Lymphocytic leukemia, MCL Mantle cell lymphoma, WM Waldenström’s Macroglobulinemia, ABC-DLBCL Activated B-cell Diffuse large B cell Lymphoma, MZL Marginal zone lymphoma, FL Follicular lymphoma, R/R relapsed or refractory, TN treatment-naïve, ORR overall response rate, CR complete response, PR partial response, Major response: complete response or at least 50% reduction in serum IgM levels